All applications must satisfy the following requirements:
- Doctoral degree (e.g., PhD, MD, DrPH, or equivalent) in medicine, social or behavioral sciences, nursing, public health, health economics, or related fields.
- Assistant professor or assistant research scientist at a medical school with a track record of NIH funding, or assistant professor or assistant research scientist at a national research university as defined by the Carnegie Foundation classification as "Research Universities" with "Very High" (RU/VH) or "High" (RU/H) Research Activity. The applicant must hold an academic appointment that focuses on conducting research rather than an academic appointment that focuses primarily on teaching. Early career research scientists at non-university affiliated research institutions will also be considered, but the institution should have a strong track record of NIH funding.
- Racial/ethnic minority background that is underrepresented in the biomedical and behavioral sciences (i.e., African American, Hispanic, American Indian/Alaska Native, Native Hawaiian, or Pacific Islanders) is preferred, but individuals from racial/ethnic minority groups that are not underrepresented in the biomedical and behavioral sciences will also be considered.
- Evidence of an established program of research in the field of drug abuse and addictions as demonstrated by peer reviewed publications in the field of drug abuse and addictions, and/or intramural grant support as either a principal investigator or co-investigator, and/or extramural grant support as a co-investigator in the field of drug abuse and the addictions. (Applicants who were a principal investigator on a K award, R03, R21, R34, R01, or a component leader of a center grant will not be considered.)
- Per institutional and NIH guidelines, applicants must not have concurrent training appointments. All applicants must be eligible to accept an appointment as a trainee in the eRA Commons xTrain system for the duration of involvement in the program.
- Preferred: Reside in the same city or metropolitan area where a NIDA Clinical Trials Network (CTN) Node is located. (For a list of CTN Nodes and locations, visit the NIDA website.)
Offers to participate in the LEAD program are contingent upon availability of funding.